Symbiotec Pharmalab Limited (SYMBIOTEC) share fundamentals
Symbiotec Pharmalab Limited is a mid-cap company in Health Care (Biotechnology) with a market capitalisation of ₹7,924 crore. Here is where it stands on valuation, profitability, debt and growth as of 5 November 2026, and how it compares with the median Health Care company.
Financial health score
Out of 100, across five pillars of reported fundamentals.
What stands out
- 12.8% promoter stake pledged
- PE of 68.7x prices in a lot of growth
- Current ratio 0.92 — short-term liabilities exceed current assets
- Negative free cash flow
Symbiotec Pharmalab Limited vs the Health Care median
| Metric | SYMBIOTEC | Sector median | |
|---|---|---|---|
| PE ratioprice paid for each rupee of yearly profit | 68.68x | 26.11x | Weaker |
| Price to bookprice against the book value of assets | 6.89x | 2.93x | Weaker |
| EV / EBITDAbusiness value against operating profit | 35.68x | 18.12x | Weaker |
| Dividend yieldyearly dividend as a share of price | — | 0.4% | |
| Return on equityprofit on shareholders’ money | 11.2% | 10.6% | In line |
| ROCEprofit on all capital employed | 14.3% | 12.7% | Better |
| Net profit marginprofit kept from each rupee of sales | 12.6% | 7.7% | Better |
| Debt to equityborrowing against shareholders’ money | 0.34x | 0.2x | Weaker |
| Interest coveragehow many times profit covers interest | 6.87x | 7.86x | Weaker |
| Current ratioshort-term assets against short-term dues | 0.92x | 1.95x | Weaker |
| Revenue growth (1Y)change in sales over a year | 15.4% | 13.9% | Better |
| EPS growth (1Y)change in earnings per share over a year | -36.6% | 8% | Weaker |
| Promoter holdingshare owned by the founders or parent | 33.3% | 56.7% | Weaker |
| Promoter pledgepromoter shares pledged as loan security | 12.8% | 0% | Weaker |
| Betahow much it moves with the market | — | 0.88 | |
| 1-year returnshare price change over 52 weeks | 16.2% | -0.6% |
Tell DecideChart your amount, timeline and target return, and AI builds a full A4 report with risks, scenarios and worst cases. Your first report is free.
Other Health Care companies
Sun Pharmaceutical Industries LimitedSUNPHARMA · score 77.8
Divi's Laboratories LtdDIVISLAB · score 76
Torrent Pharmaceuticals LtdTORNTPHARM · score 63.7
Laurus Labs LtdLAURUSLABS · score 67.5
Apollo Hospitals Enterprise LimitedAPOLLOHOSP · score 59.5
Zydus Lifesciences LtdZYDUSLIFE · score 80
Dr. Reddy's Laboratories LimitedDRREDDY · score 67.9
Cipla LtdCIPLA · score 68.1
Mankind Pharma LtdMANKIND · score 57.4
Aurobindo Pharma LimitedAUROPHARMA · score 73.4
Lupin LimitedLUPIN · score 91.9
Max Healthcare Institute LimitedMAXHEALTH · score 59.9Frequently asked questions
What is the PE ratio of Symbiotec Pharmalab Limited?
Symbiotec Pharmalab Limited trades at a PE of 68.68x as of 5 November 2026, against a Health Care median of 26.11x. PE is the price paid for each rupee of yearly profit.
Is Symbiotec Pharmalab Limited debt free?
No. Symbiotec Pharmalab Limited has a debt-to-equity ratio of 0.34x, against a Health Care median of 0.2x.
What is the ROCE and ROE of Symbiotec Pharmalab Limited?
Symbiotec Pharmalab Limited has a return on capital employed of 14.3% and a return on equity of 11.2%. The Health Care medians are 12.7% and 10.6%.
What is the DecideChart health score of Symbiotec Pharmalab Limited?
Symbiotec Pharmalab Limited scores 48.9 out of 100, graded Caution. The score weighs profitability, debt, valuation, growth and governance from the company’s reported numbers. It is a research aid, not a recommendation.
Should I buy Symbiotec Pharmalab Limited shares?
DecideChart does not give buy or sell tips and is not linked to SEBI, BSE or NSE. Use these numbers for your own research, compare Symbiotec Pharmalab Limited with its Health Care peers, and consult a SEBI-registered adviser before investing.
Fundamentals from a public market-data screener, as of 5 November 2026. Figures can lag company filings. DecideChart is AI-based, not linked to SEBI, BSE or NSE, and does not give investment advice.